ID: ALA2381022

Max Phase: Preclinical

Molecular Formula: C19H21ClN2O3

Molecular Weight: 360.84

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1CC(=O)N([C@H]2C[C@H]3CC[C@@H]2C3)C(=O)N1CCc1cccc(Cl)c1

Standard InChI:  InChI=1S/C19H21ClN2O3/c20-15-3-1-2-12(9-15)6-7-21-17(23)11-18(24)22(19(21)25)16-10-13-4-5-14(16)8-13/h1-3,9,13-14,16H,4-8,10-11H2/t13-,14+,16-/m0/s1

Standard InChI Key:  DCCFYCBYFZNPGZ-LZWOXQAQSA-N

Associated Targets(non-human)

CACNA1C Voltage-gated L-type calcium channel alpha-1C subunit (335 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cacna1d Voltage-gated L-type calcium channel alpha-1D subunit (336 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 360.84Molecular Weight (Monoisotopic): 360.1241AlogP: 3.25#Rotatable Bonds: 4
Polar Surface Area: 57.69Molecular Species: ACIDHBA: 3HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: 5.00CX Basic pKa: CX LogP: 3.34CX LogD: 1.00
Aromatic Rings: 1Heavy Atoms: 25QED Weighted: 0.77Np Likeness Score: -0.79

References

1. Kang S, Cooper G, Dunne SF, Luan CH, Surmeier DJ, Silverman RB..  (2013)  Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease.,  56  (11): [PMID:23651412] [10.1021/jm4005048]

Source